The markets refuse to forgive Infinity

Infinity has had quite the journey in PI3K inhibition, having given up on its most advanced project, duvelisib, and sold it to Verastem for zero up front in 2016. The focus turned to the gamma-selective asset eganelisib, which today had its judgement day; the markets did not like what they saw.